Metformin use tied to early risk of anaemia in type 2 diabetes

  • Donnelly LA & al.
  • Diabetes Care
  • 14 Aug 2020

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Metformin use was associated with an early reduction in haemoglobin (Hb) and increased rates of moderate anaemia in patients with type 2 diabetes (T2D), and this finding was consistent across two randomised controlled trials (RCTs) and replicated in one real-world study of routinely collected data.

Why this matters

  • Because the mechanisms for metformin-related moderate anaemia are unknown, the effects are modest, and the benefits of metformin are proven, the authors do not advocate avoidance or discontinuation even in patients with anaemia, but a reduction in Hb in the first few years after initiation might be anticipated.

Study design

  • Association between metformin use and anaemia risk in T2D and the time course for this were evaluated in the A Diabetes Outcome Progression Trial (ADOPT; n=3967) and UK Prospective Diabetes Study (UKPDS; n=1473) RCTs.
  • The cumulative effect was evaluated in the observational Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS) population (n=3485).
  • Funding: Medical Research Council.

Key results

  • In ADOPT, compared with sulphonylureas, the OR for anaemia was 1.93 (95% CI, 1.10-3.38) for metformin and 4.18 (95% CI, 2.50-7.00) for thiazolidinediones (TZDs).
  • In UKPDS, compared with diet, the OR for anaemia was 3.40 (95% CI, 1.98-5.83) for metformin, 0.96 (95% CI, 0.57-1.62) for sulphonylureas and 1.08 (95% CI, 0.62-1.87) for insulin.
  • In ADOPT, Hb and haematocrit levels dropped by 6 months in both metformin and TZDs groups with no further Hb decrease between 3 and 5 years.
  • In UKPDS, Hb levels dropped by 3 years with metformin treatment vs other treatments.
  • At 6 and 9 years, Hb levels were reduced in all treatment groups with no greater further fall seen in the metformin vs diet-treated group (0.49 g/dL [95% CI, -1.64 to 2.62] vs 0.50 g/dL [95% CI, -1.71 to 2.72] fall from 3 to 9 years).
  • In GoDARTS, each 1 g/day of metformin use was associated with a 2% increased annual risk of anaemia.

Limitations

  • Lack of vitamin B12 measurement.
  • Post hoc analysis of RCT data.